SI-BONE Inc

SI-BONE, Inc. engages in the provision of implantable devices used in the surgical treatment of the sacropelvic anatomy. It offers a proprietary minimally invasive surgical implant system, called iFuse, used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. The company was founded by Mark A. Reiley and Jeffrey W. Dunn on March 2008 and is headquartered in Santa Clara, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SI-BONE reports record Q4 revenue, eyes global growth opportunities

SI-BONE's Q4 2022 performance reflects robust revenue growth and operational improvements, driven by increased surgeon engagement and product adoption.
The company's financial stability, strong cash position, and strategic focus on growth opportunities position it well for future success and market expansion.
While facing challenges such as undisclosed study enrollment and international growth pacing, SI-BONE's focus on operational efficiency and market opportunities presents a positive outlook for sustained growth and profitability.

SI-BONE Inc reports robust Q1 revenue growth and raises 2023 guidance

SI-BONE Inc had a strong Q1 performance with robust revenue growth and surgeon adoption. While facing some challenges with expense increases, the company is optimistic about future growth opportunities and aims for improved financial performance throughout 2023.

SI-BONE Inc reports robust Q2 growth and optimistic outlook

SI-BONE Inc's Q2 2023 showcased strong revenue growth, improved operational efficiency, and enhanced cash position.
Company's product portfolio, FDA clearances, and revenue guidance revisions underscore its growth potential and market competitiveness.
Challenges include managing increased operating expenses, evolving marketing strategies, and maintaining growth momentum.
Opportunities lie in expanding surgeon base, leveraging training programs, conducting market studies, and aiming for a strong second half performance.

SI-BONE reports record revenue in Q3 2023, eyes market expansion

SI-BONE's Q3 2023 earnings call showcased robust financial performance, strong market positioning, and growth prospects. With record revenue, increased guidance, and a focus on innovation and market expansion, SI-BONE is well-positioned for continued success in the medical device industry.

SI-BONE reports record revenue growth and strategic product launches

SI-BONE Inc delivered strong financial performance in Q4 2023, with record revenue, improved EBITDA, and a solid cash position for future growth initiatives.
The company's strategic strengths lie in its U.S. market dominance, innovative product launches, and positive revenue guidance for 2024.
Challenges include expanding international revenue, pricing competitiveness, and effective training for new products, while opportunities exist in market expansion and product innovation.
Overall, SI-BONE's performance highlights its resilience, growth potential, and strategic focus on driving innovation and market expansion in the medical device sector.

SI-BONE Inc reports robust Q1 revenue growth and strategic focus

SI-BONE Inc's Q1 performance reflects strong revenue growth and operational achievements, underpinned by strategic priorities and market differentiation. While facing challenges in expense management and profitability, the company is well-positioned to capitalize on opportunities through innovation and market disruption.

SI-BONE Inc reports strong Q2 earnings, eyes growth opportunities

SI-BONE Inc delivered robust financial performance in Q2 2024, driven by revenue growth, increased active physicians, and improved EBITDA.
The company's strengths lie in customer loyalty, innovation, leadership enhancements, and a clear path to financial sustainability.
Challenges include operational scalability, sustaining revenue growth, balancing innovation with cost control, and effective Board integration.
Opportunities for SI-BONE include accelerating revenue growth, expanding into new market segments, diversifying product offerings, and leveraging strategic Board additions.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SI-BONE, Inc. is a medical device company, which engages in the provision of a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of musculoskeletal disorders of the sacropelvic anatomy. It offers a proprietary minimally invasive surgical implant system, called iFuse, used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. The company was founded by Mark A. Reiley and Jeffrey W. Dunn on March 18, 2008 and is headquartered in Santa Clara, CA.

SANTA CLARA, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, December 4, 2024, at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time.

SI-BONE To Present at Piper Sandler 36th Annual Healthcare Conference on December 4, 2024

SI-BONE, Inc. (NASDAQ:SIBN ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Saqib Iqbal - Senior Director of Investor Relations Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants Craig Bijou - BofA Securities Young Li - Jefferies Drew Ranieri - Morgan Stanley Caitlin Cronin - Canaccord Richard Newitter - Truist Securities Operator Good afternoon, and welcome to SI-BONE's Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

SI-BONE, Inc. (SIBN) Q3 2024 Earnings Call Transcript

Si-Bone (SIBN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.25 per share a year ago.

Si-Bone (SIBN) Reports Q3 Loss, Lags Revenue Estimates

SANTA CLARA, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the quarter ended September 30, 2024.

SI-BONE, Inc. Reports Financial Results for the Third Quarter 2024 and Updates Guidance

The iFuse Bedrock Granite™ system is a Breakthrough Device Designation technology that provides pelvic fixation and sacroiliac joint fusion, in conjunction with lumbar spinal fusion procedures The iFuse Bedrock Granite™ system is a Breakthrough Device Designation technology that provides pelvic fixation and sacroiliac joint fusion, in conjunction with lumbar spinal fusion procedures

SI-BONE Receives Transitional Pass-Through Payment Status for iFuse Bedrock Granite™

Si-Bone (SIBN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Si-Bone (SIBN): Can Its 6.9% Jump Turn into More Strength?

SANTA CLARA, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

SI-BONE To Report Third Quarter 2024 Financial Results on November 12, 2024

SI-BONE aims to address the unmet clinical needs of complex pelvic fragility fractures by providing a solution that improves both surgical efficiency and patient recovery.

SIBN Stock Up After First-In-Patient Use of FDA Breakthrough Device

SANTA CLARA, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, today announced first-in-patient procedures with the FDA-designated breakthrough device, iFuse TORQ TNT™ Implant System (TNT). Designed to address the anatomic and biomechanical challenges of pelvic fragility fractures, particularly in patients with poor bone quality, TNT offers a significant advancement over traditional cannulated screws.

SI-BONE, Inc. Announces First-In-Patient Procedures with FDA Breakthrough Device for Pelvic Fracture Fixation

The average of price targets set by Wall Street analysts indicates a potential upside of 40.3% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Si-Bone (SIBN) Could Surge 40.3%: Read This Before Placing a Bet

SI-BONE (SIBN) receives FDA 510(k) clearance for its iFuse TORQ TNT implant system, followed by a Breakthrough Device Designation award by the FDA.

SI-BONE (SIBN) Receives FDA Nod for Its TNT Implant System

SANTA CLARA, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, September 4, 2024, at 10:45 a.m. Eastern Time / 7:45 a.m. Pacific Time.

SI-BONE To Present at Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024

SANTA CLARA, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, announces FDA 510(k) clearance of the iFuse TORQ TNT™ Implant System (TNT). The TNT implant system is designed to meet the specific anatomical and bone mineral density needs of the sacrum and ilium and will serve as the next generation technology for pelvic fragility fracture fixation and sacroiliac joint fusion.

SI-BONE, Inc. Receives 510(k) Clearance and FDA Breakthrough Device Designation for Pelvic Fracture Fixation System

The consensus price target hints at a 64.5% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 64.45%: Here's is How to Trade

SANTA CLARA, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will be participating in the upcoming 2024 Canaccord Genuity 44th Annual Growth Conference in Boston. Management will be hosting a fireside chat on Wednesday, August 14th, 2024, at 3:30 p.m. Eastern Time/ 1:30 p.m. Pacific Time.

SI-BONE To Present at Canaccord Genuity 44th Annual Growth Conference on August 14, 2024

SI-BONE, Inc. (NASDAQ:SIBN ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants Saqib Iqbal - Senior Director of Investor Relations Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants Matthew O'Brien - Piper Sandler Andrew Ranieri - Morgan Stanley Xuyang Li - Jefferies Caitlin Cronin - Canaccord Genuity David Turkaly - Citizens JMP Ross Osborn - Cantor Fitzgerald Operator Good afternoon and welcome to SI-BONE's Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

SI-BONE, Inc. (SIBN) Q2 2024 Earnings Call Transcript

Si-Bone (SIBN) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.30 per share a year ago.

Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates

Increases 2024 revenue guidance to $165 million - $167 millionExpects to achieve positive Adjusted EBITDA in Fourth Quarter 2024

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2024

Abbott Labs

Edwards Lifesciences

Glaukos

iRhythm Technologies

Johnson & Johnson

Inari Medical

While technology lately has been framed in the context of computer hardware or software, it can also apply to the broader field of medicine. Therefore, investors should consider the viable field of MedTech stocks.

7 Leading MedTech Stocks for Next-Gen Health Solutions

SANTA CLARA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the second quarter of 2024 after market close on Monday, August 5, 2024. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

SI-BONE To Report Second Quarter 2024 Financial Results on August 5, 2024

SANTA CLARA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2024 Truist Securities MedTech Conference in Boston. Management will be hosting a fireside chat on Tuesday, June 18, at 3:40 p.m. Eastern Time / 12:40 p.m. Pacific Time.

SI-BONE To Present at Truist Securities 2024 MedTech Conference on June 18, 2024

SANTA CLARA, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced the first cases completed with the smaller, 9.5 mm diameter, iFuse Bedrock Granite® Implant (Granite 9.5). When placed across the SI joint, the Granite implant provides sacroiliac fusion and spinopelvic fixation as a foundational element for multi-segment spinal fusion.

SI-BONE Expands Portfolio with the Launch of New Offering for the iFuse Bedrock Granite Implant System and Completes Inaugural Surgical Procedures

SI-BONE, Inc. (NASDAQ:SIBN ) Q1 2024 Results Conference Call May 6, 2024 4:30 PM ET Company Participants Saqib Iqbal - Senior Director, Investor Relations Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants Craig Bijou - Bank of America Securities Matthew O'Brien - Piper Sandler Drew Ranieri - Morgan Stanley Dave Turkaly - Citizen JMP Caitlin Cronin - Canaccord Genuity David Saxon - Needham & Company Sam Brodovsky - Truist Securities Ross Osborn - Cantor Fitzgerald Operator Good afternoon and welcome to SI-Bone First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

SI-BONE, Inc. (SIBN) Q1 2024 Earnings Call Transcript

Si-Bone (SIBN) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.32 per share a year ago.

Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates

Annual guidance increased to $164 million - $166 million, implying annual growth of ~18% - 20% Annual guidance increased to $164 million - $166 million, implying annual growth of ~18% - 20%

News for SI-BONE Inc Stock (SIBN)